RBC Capital raised the firm’s price target on Ideaya Biosciences (IDYA) to $41 from $38 and keeps an Outperform rating on the shares. Ideaya Biosciences presented data on eye and visual acuity preservation from daro in the neo-adjuvant setting, suggesting evidence of very impressive anti-tumor efficacy leading to meaningful survival benefits, eye preservation and visual benefits, increasing the likelihood that upcoming phase III trials will read out positively, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- Promising Potential of IDEAYA Biosciences’ Darovasertib: Strong Efficacy and Safety in Uveal Melanoma Trials
- IDEAYA Biosciences Presents Promising Phase 2 Data
- IDEAYA Biosciences: Promising Phase 1/2 Trial Results and Strong Upside Potential Justify Buy Rating
- Ideaya Biosciences presents clinical data from OptimUM-09 trial
- Ideaya Biosciences reports overall survival data from darovasertib trial